{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:03:21Z","timestamp":1759104201507,"version":"3.44.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jneuroim.2017.05.015","type":"journal-article","created":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T08:45:43Z","timestamp":1495615543000},"page":"82-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The c-Abl inhibitor, nilotinib, as a potential therapeutic agent for chronic cerebellar ataxia"],"prefix":"10.1016","volume":"309","author":[{"given":"Woo-Jin","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jangsup","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Sun","family":"Jun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Sang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Jin","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon-Tae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keun-Hwa","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Il","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Young","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Kun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kon","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2017.05.015_bb0005","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/brain\/awf107","article-title":"The aetiology of sporadic adult-onset ataxia","volume":"125","author":"Abele","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0010","doi-asserted-by":"crossref","first-page":"10390","DOI":"10.1523\/JNEUROSCI.3458-05.2005","article-title":"Neurobiological mechanisms of the placebo effect","volume":"25","author":"Benedetti","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1399-0004.2006.00722.x","article-title":"Diagnosis and management of early-and late-onset cerebellar ataxia","volume":"71","author":"Brusse","year":"2007","journal-title":"Clin. Genet."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0020","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/brain\/119.5.1497","article-title":"Autosomal dominant cerebellar ataxia type I clinical features and MRI in families with SCA1, SCA2 and SCA3","volume":"119","author":"B\u00fcrk","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0025","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1523\/JNEUROSCI.23-10-04066.2003","article-title":"Evidence for protein tyrosine phosphatase, tyrosine kinase, and G-protein regulation of the parallel fiber metabotropic slow EPSC of rat cerebellar Purkinje neurons","volume":"23","author":"Canepari","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0035","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1523\/JNEUROSCI.18-10-03606.1998","article-title":"The glutamate transporter EAAT4 in rat cerebellar Purkinje cells: a glutamate-gated chloride channel concentrated near the synapse in parts of the dendritic membrane facing astroglia","volume":"18","author":"Dehnes","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0040","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1523\/JNEUROSCI.16-11-03760.1996","article-title":"Metabotropic glutamate receptor activation in cerebellar Purkinje cells as substrate for adaptive timing of the classically conditioned eye-blink response","volume":"16","author":"Fiala","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0045","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0050","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1074\/jbc.275.17.12725","article-title":"Interaction of the N-methyl-d-aspartic acid receptor NR2D subunit with the c-Abl tyrosine kinase","volume":"275","author":"Glover","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0055","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/683097","article-title":"Oxidative stress, DNA damage, and c-Abl signaling: at the crossroad in neurodegenerative diseases?","volume":"2012","author":"Gonfloni","year":"2012","journal-title":"Int. J. Cell Biol."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0060","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in Parkinson's disease models","author":"Hebron","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0065","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/jnc.13763","article-title":"Tyrosine kinase inhibition reverses TDP-43 effects on synaptic protein expression, astrocytic function and amino acid dis-homeostasis","volume":"139","author":"Heyburn","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0070","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jamaneurol.2016.0232","article-title":"Association of progressive cerebellar atrophy with long-term outcome in patients with anti-N-methyl-d-aspartate receptor encephalitis","volume":"73","author":"Iizuka","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065129","article-title":"Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model","volume":"8","author":"Imam","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0080","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1038\/srep04874","article-title":"The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease","volume":"4","author":"Karuppagounder","year":"2014","journal-title":"Sci. Report."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046185","article-title":"c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis","volume":"7","author":"Katsumata","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0090","first-page":"67","article-title":"Hereditary cerebellar ataxias: a Korean perspective","volume":"8","author":"Kim","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0095","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/14734220510007950","article-title":"The pathogenesis of spinocerebellar ataxia","volume":"4","author":"Koeppen","year":"2005","journal-title":"Cerebellum"},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.14581\/jer.16010","article-title":"The laboratory diagnosis of autoimmune encephalitis","volume":"6","author":"Lee","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0105","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1212\/WNL.0000000000002635","article-title":"Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort","volume":"86","author":"Lee","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083914","article-title":"Ubiquitination increases parkin activity to promote autophagic \u03b1-synuclein clearance","volume":"8","author":"Lonskaya","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0115","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/emmm.201302771","article-title":"Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance","volume":"5","author":"Lonskaya","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0120","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00109-013-1112-3","article-title":"Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance","volume":"92","author":"Lonskaya","year":"2014","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0125","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/ana.21123","article-title":"Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases","volume":"61","author":"Manto","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0130","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib effects in Parkinson's disease and dementia with Lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0135","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0140","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(04)00737-9","article-title":"Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis","volume":"3","author":"Sch\u00f6ls","year":"2004","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0145","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/brain\/awg133","article-title":"Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients","volume":"126","author":"Shams'ili","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0150","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0896-6273(94)90441-3","article-title":"Antibodies inactivating mGluR1 metabotropic glutamate receptor block long-term depression in cultured Purkinje cells","volume":"12","author":"Shigemoto","year":"1994","journal-title":"Neuron"},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM200001063420104","article-title":"Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor","volume":"342","author":"Smitt","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0160","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00234-003-0945-9","article-title":"Ataxia-telangiectasia: the pattern of cerebellar atrophy on MRI","volume":"45","author":"Tavani","year":"2003","journal-title":"Neuroradiology"},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0165","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/205713","article-title":"Oxidative stress: a pathogenic mechanism for Niemann-Pick type C disease","volume":"2012","author":"V\u00e1zquez","year":"2012","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0170","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/nn1539","article-title":"Patterned expression of Purkinje cell glutamate transporters controls synaptic plasticity","volume":"8","author":"Wadiche","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jneuroim.2017.05.015_bb0175","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nn1648","article-title":"Decreases in the precision of Purkinje cell pacemaking cause cerebellar dysfunction and ataxia","volume":"9","author":"Walter","year":"2006","journal-title":"Nat. Neurosci."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572817301327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572817301327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:29:44Z","timestamp":1759048184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572817301327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":34,"alternative-id":["S0165572817301327"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2017.05.015","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The c-Abl inhibitor, nilotinib, as a potential therapeutic agent for chronic cerebellar ataxia","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2017.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}